Prostate Cancer Epigenetics - from Pathophysiology to Clinical Application

Overview

Journal Nat Rev Urol

Date 2025 Jan 17

PMID 39820138

Authors

Vera Constancio

Joao Lobo

Jose Pedro Sequeira

Rui Henrique

Carmen Jeronimo

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a multifactorial disease influenced by various molecular features. Over the past decades, epigenetics, which is the study of changes in gene expression without altering the DNA sequence, has been recognized as a major driver of this disease. In the past 50 years, advancements in technological tools to characterize the epigenome have highlighted crucial roles of epigenetic mechanisms throughout the entire spectrum of prostate cancer, from initiation to progression, including localized disease, metastatic dissemination, castration resistance and neuroendocrine transdifferentiation. Substantial advances in the understanding of epigenetic mechanisms in the pathophysiology of prostate cancer have been carried out, but translating preclinical achievements into clinical practice remains challenging. Ongoing research and biomarker-oriented clinical trials are expected to increase the likelihood of successfully integrating epigenetics into prostate cancer clinical management.

References

Wong M, Goggins W, Wang H, Fung F, Leung C, Wong S . Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol. 2016; 70(5):862-874. DOI: 10.1016/j.eururo.2016.05.043. View

Dy G, Gore J, Forouzanfar M, Naghavi M, Fitzmaurice C . Global Burden of Urologic Cancers, 1990-2013. Eur Urol. 2016; 71(3):437-446. DOI: 10.1016/j.eururo.2016.10.008. View

Hugosson J, Roobol M, Mansson M, Tammela T, Zappa M, Nelen V . A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019; 76(1):43-51. PMC: 7513694. DOI: 10.1016/j.eururo.2019.02.009. View

Auvinen A . Prostate cancer: Prudent practice optimizes screening outcomes. Nat Rev Urol. 2016; 13(7):376-7. DOI: 10.1038/nrurol.2016.90. View

Nelson W, De Marzo A, Isaacs W . Prostate cancer. N Engl J Med. 2003; 349(4):366-81. DOI: 10.1056/NEJMra021562. View

Conteduca V, Hess J, Yamada Y, Ku S, Beltran H . Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021; 10(7):3104-3116. PMC: 8350251. DOI: 10.21037/tau-20-1339. View

Jeronimo C, Bastian P, Bjartell A, Carbone G, Catto J, Clark S . Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011; 60(4):753-66. DOI: 10.1016/j.eururo.2011.06.035. View

Cavalli G, Heard E . Advances in epigenetics link genetics to the environment and disease. Nature. 2019; 571(7766):489-499. DOI: 10.1038/s41586-019-1411-0. View

Besselink N, Keijer J, Vermeulen C, Boymans S, de Ridder J, Van Hoeck A . The genome-wide mutational consequences of DNA hypomethylation. Sci Rep. 2023; 13(1):6874. PMC: 10140063. DOI: 10.1038/s41598-023-33932-3. View

10.

Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W . Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024; 10(1):28. PMC: 10789753. DOI: 10.1038/s41420-024-01803-z. View

11.

Anastasiadou E, Jacob L, Slack F . Non-coding RNA networks in cancer. Nat Rev Cancer. 2017; 18(1):5-18. PMC: 6337726. DOI: 10.1038/nrc.2017.99. View

12.

Costa-Pinheiro P, Ramalho-Carvalho J, Vieira F, Torres-Ferreira J, Oliveira J, Goncalves C . MicroRNA-375 plays a dual role in prostate carcinogenesis. Clin Epigenetics. 2015; 7:42. PMC: 4431534. DOI: 10.1186/s13148-015-0076-2. View

13.

Ramalho-Carvalho J, Fromm B, Henrique R, Jeronimo C . Deciphering the function of non-coding RNAs in prostate cancer. Cancer Metastasis Rev. 2016; 35(2):235-62. DOI: 10.1007/s10555-016-9628-y. View

14.

Zhao S, Allis C, Wang G . The language of chromatin modification in human cancers. Nat Rev Cancer. 2021; 21(7):413-430. PMC: 10507815. DOI: 10.1038/s41568-021-00357-x. View

15.

Perry A, Watson R, Lawler M, Hollywood D . The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol. 2010; 7(12):668-80. DOI: 10.1038/nrurol.2010.185. View

16.

Graca I, Pereira-Silva E, Henrique R, Packham G, Crabb S, Jeronimo C . Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics. 2016; 8:98. PMC: 5025578. DOI: 10.1186/s13148-016-0264-8. View

17.

Lovf M, Zhao S, Axcrona U, Johannessen B, Bakken A, Carm K . Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. Eur Urol. 2018; 75(3):498-505. DOI: 10.1016/j.eururo.2018.08.009. View

18.

Boutros P, Fraser M, Harding N, De Borja R, Trudel D, Lalonde E . Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015; 47(7):736-45. DOI: 10.1038/ng.3315. View

19.

Cooper C, Eeles R, Wedge D, Van Loo P, Gundem G, Alexandrov L . Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015; 47(4):367-372. PMC: 4380509. DOI: 10.1038/ng.3221. View

20.

Eksi S, Chitsazan A, Sayar Z, Thomas G, Fields A, Kopp R . Epigenetic loss of heterogeneity from low to high grade localized prostate tumours. Nat Commun. 2021; 12(1):7292. PMC: 8674326. DOI: 10.1038/s41467-021-27615-8. View